A Multicenter, Open-Label, Single Agent, Two-Stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Malignant Glioma.

Trial Profile

A Multicenter, Open-Label, Single Agent, Two-Stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Malignant Glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Rilotumumab (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 06 Feb 2014 According to ClinicalTrials.gov record trial status changed to completed.
    • 09 Dec 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 21 Apr 2011 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top